Chapter 2 Summary and Highlights
- Market Outlook
- Market Insights
Chapter 3 Market Overview
- Market Overview
- Theranostics and Personalized Medicines Overview
- Nanoparticles
- Passive Targeting
- Active Targeting
- Nanotechnology Overview
- Size Definition
- Shape
- Surface Area
- Nanotheranostic Drug Delivery
- In Vivo Drug-Release Studies
- Drug Efficacy
- Future Perspectives
Chapter 4 Nanodevices and Nanomaterials in Diagnostics
- Overview
- Molecular Recognition in Diagnosis
- Nanopatterned Devices
- Particles
- Carbon Nanotubes
- Carbon Nanotubes as a Carriers of Immunoactive Compounds, Proteins and Genetic Materials
- Cancer Photothermal Therapy
- Carbon Nanotubes for Other Therapeutic Applications
- Fullerene C60
- C60 Toxicity
- Uptake and Biodistribution
- Antioxidant Properties
- Endohedrals
- Magnetic Resonance Imaging
- Radionuclides
- Photodynamic Therapy
- Dna Photocleavage
- Cancer
- Enzymes, Viruses, and Bacteria Inhibition
- Drug and Gene Delivery
- Magnetic Nanoparticles
- Hyperthermia
- Magnetic Separation
- Imaging and Delivery
- Brain Tumor Delivery
- Prostate Cancer
- Bladder Tumors
- Quantum Dots
- Aptamer-Conjugated Nanoparticles
- Nanoparticle-Based Bio-Bar Codes
- Multiplex Dendrimers
- Surface Enhanced Raman Spectroscopy
- Diagnostic and Medical Device Industry
- Multifunctional Nanoparticles
- Polymeric Nanoparticles in Cancer Therapy
- Polymeric-Based Imaging Probes for Cancer Imaging
- Quantum Dots in Cancer Imaging and Therapy
- Quantum Dots in Photodynamic Therapy and Imaging
- Multifunctional Imaging Nanoparticles for Cancer Imaging and Therapy
- Magnetic Nanoparticles for Magnetic Resonance Imaging and Gene Delivery
- Multifunctional Magneto-Polymeric Nanohybrids for Cancer Imaging and Therapy
- Gold Nanoparticles for Photothermal Therapy
- Gold Nanoshells
- Gold Nanorods
- Magnetic Gold Nanoshells for Photothermal Therapy and Imaging
- Conclusion and Future Trends
Chapter 5 Treatments Based on Nanomaterial for Infections Associated with Medical Devices
- Infections Associated with Medical Devices and Their Treatments
- Catheter-Associated Infections
- Soft-Tissue-Implant-Associated Infections
- Biofilm Formation
- Common Methods for Preventing and Treating Medical Device-Associated Infections
- Nanomaterials in Medical Applications
- Nanomaterials in Personalized Medicine
- Antimicrobial Nanomaterials
- Silver Nanoparticles
- Zinc Oxide
- Iron and Iron-Oxide Nanoparticles
- Titanium Oxide
- Carbon Nanotubes and Fullerenes
- Chitosan
- Cytotoxicity Consideration
Chapter 6 Biomedical Nanoparticle Products
- Introduction
- Contract Manufacturing Organizations
- Information Technology
- Nanoparticle Drug Delivery Systems and Products
- Nanoparticle Drug Delivery Systems
- Company Pipelines for Nanoparticle Drug Delivery
Chapter 7 Therapeutic and Diagnostic Companion Kits
Chapter 8 Market Dynamics
- Market Drivers
- Rising Prevalence of Chronic Diseases Globally
- Rising Cancer Cases Globally
- Cancer Mortality
- Increasing Number of Diabetes Cases Worldwide
- Rising Worldwide Cases of Hypercholesterolemia
- Other Major Drivers in the Personalized Medicine Market Are:
- Market Restraints
- Challenges with Personalized Medicine
- Market Opportunities
- Nanodrug Delivery for the Treatment of Neurological Disorders
- Increasing Government Investment in Healthcare Sectors
- Rising Healthcare Costs
- Consumer Expectations
Chapter 9 Regulatory Landscape
- Overview
- Physicochemical Properties of Nanoproducts Differ Compared to Their Larger Counterparts
- Regulatory Issues in Nanotechnology
- Nanomedicines in the Pharmaceutical Market
- Market Access and Pharmacoeconomics
Chapter 10 Impact of COVID-19 on the Market
- Overview
- Structure of COVID-19 and Penetration
- COVID-19 Crisis
- Impact of COVID-19 on Nanomaterials in Personalized Medicine
- Novel Coronavirus Relying on Various Approaches
- Challenges in Vaccine Disruptions
- Components and Methods in the Design of a Vaccine
- Antigens
- Adjuvants
- Nanoparticles/Nanocarriers
- Devices
- Next-Generation Vaccines Enabled Through Advances in Nanotechnology
- Conclusions Regarding Use of Nanotechnology to Combat COVID-19
- COVID-19 Measures
Chapter 11 Market Breakdown by Product Type
- Market Overview
- Proteins
- Monoclonal Antibodies (Mabs)
- Monoclonal Antibody Therapy
- Mechanism
- Nanocrystals
- Nanocrystals Fabrication
- Liposomes
- Liposome Classification and Preparation
- Sonication
- Extrusion
- Freeze-Thawed Liposomes
- Solvent Dispersion Method
- Detergent-Removal Method
- Stealth Liposome
- Antibody-Liposome Conjugate
- Liposome Application in Medicine and Pharmacology
- Liposomes in Parasite Diseases and Infections
- Liposomes in Anticancer Therapies
- In Vitro Optical Imaging
- Gold Nanocarrier
- Hyperthermia
- Contrast Enhancers
- Radiotherapy
- Quantum Dots as Nanocarriers
- Photophysical Properties, Drug-Delivery and Drug-Release Sensing
- Visualizing Intracellular Uptake in Vitro
- Nanocarrier Biodistribution in Vivo
- Short Interfering Rna and Dna Delivery
Chapter 12 Market Breakdown by Region
- Overview
- North America
- U.S. Market Size and Forecast
- Canada Market Size and Forecast
- Europe
- Germany Market Size and Forecast
- U.K. Market Size and Forecast
- France Market Size and Forecast
- Italy Market Size and Forecast
- Spain Market Size and Forecast
- Rest of European Market Size and Forecast
- Asia-Pacific
- China Market Size and Forecast
- Japan Market Size and Forecast
- India Market Size and Forecast
- South Korea Market Size and Forecast
- Rest of Asia-Pacific Market Size and Forecast
- Rest of the World
- South America Market Size and Forecast
- Middle East and Africa Market Size and Forecast
Chapter 13 Esg Development
- Introduction to Esg
- Environmental
- Social
- Government
- The Sustainability of Major Companies in the Industry
- Pharma End-user Sustainability in the Industry
- Case Study
- Concluding Remarks
Chapter 14 Emerging Technologies
- Overview
- Current Market Trends
- Emerging Technologies
- Biomarkers
- Deep Phenotyping Technologies
- Digital Precision Medicine
- Genetics
- Health Information Technology
Chapter 15 Patents and Pipeline Analysis
- Overview
- Patent Analysis
- Pipeline Analysis
Chapter 17 Competitive Landscape
- Overview
- Distribution of Nanobiotechnology and Nanomedicine Companies
- Company Share Analysis
Chapter 18 Company Profiles
- Bristol-Myers Squibb
- Camurus Ab
- Cytimmune Sciences
- Eisai
- Gilead Sciences Inc.
- Ipsen Pharma
List of Tables
Summary Table: Global Market for Nanomaterials in Personalized Medicine, by Product Type, Through 2028
Table A: Types of Nanomaterials
Table B: Major Nanomaterial Applications in Personalized Medicine
Table 1: Therapies with Diagnostic Companion Kits
Table 2: Nanoparticle Systems Approved for Drug Delivery
Table 3: Imaging Modalities Used in Theranostics Nanodevices
Table 4: Nanoparticles Contrast Media Used for In Vivo Diagnostic Imaging
Table 5: Major Players in Nanoparticle Drug Development and Formulation Market
Table 6: Nanoparticles Used in Drug Delivery Systems
Table 7: List of Marketed Products Used in Different Nanotechnology-Based Techniques
Table 8: Major Companies in the Market for Nanoparticle Drug Development and Formulation
Table 9: Company Pipelines for Cardiovascular Nanoparticle Drugs
Table 10: Company Pipelines for CNS Disease Nanoparticle Drugs
Table 11: Company Pipelines for GI Disease Nanoparticle Drugs
Table 12: Company Pipelines for Infectious Disease Nanoparticle Drugs
Table 13: Company Pipelines for Cancer Nanoparticle Drugs
Table 14: Company Pipelines for Ophthalmic Nanoparticle Drugs
Table 15: Company Pipelines for Autoimmune Disease Nanoparticle Drugs
Table 16: Global Prevalence of Breast Cancer, by Country/Region, Through 2025
Table 17: Global Epidemiology of Colorectal Cancer, by Region, Through 2030
Table 18: Global Deaths, by Various Cancer Types, Through 2030
Table 19: Global Death Share, by Various Cancer Types, 2021
Table 20: Global Diabetes Prevalence, Estimates and Projections, 2019-2045
Table 21: Cases of Diabetes Worldwide, by Type, 2019
Table 22: Global Prevalence of Diabetes, by Type, Through 2040
Table 23: Global Totals of Angina Pectoris and Stroke Survivors, Through 2030
Table 24: Global Incidence and Prevalence of all Stroke Types, 2019
Table 25: Global Prevalence of Congestive Heart Failure and Stroke, Through 2030
Table 26: Global Market for Nanomaterials in Personalized Medicine, by Product Type, Through 2028
Table 27: Products of Non-monoclonal Antibody Proteins
Table 28: Global Market for Proteins in Personalized Medicine, by Region, Through 2028
Table 29: Major Companies in the Market for Monoclonal Antibodies
Table 30: Indications of Monoclonal Antibody Products
Table 31: Global Market for Monoclonal Antibodies in Personalized Medicine, by Region, Through 2028
Table 32: Properties of Nanocrystals
Table 33: Nanocrystal Drug Features
Table 34: Nanocrystal Fabrication Methods
Table 35: Nanocrystal Drugs Currently on the Market
Table 36: Global Market for Nanocrystals in Personalized Medicine, by Region, Through 2028
Table 37: Liposome Advantages
Table 38: Liposome-Based Drugs
Table 39: Major Companies in the Liposomes Market
Table 40: Global Market for Liposomes in Personalized Medicine, by Region, Through 2028
Table 41: Global Market for Gold Nanoparticles in Personalized Medicine, Through 2028
Table 42: Global Market for Quantum Dots in Personalized Medicine, Through 2028
Table 43: Global Market for Nanomaterials in Personalized Medicine, by Region, Through 2028
Table 44: Diabetes Estimates in North America, by Country, 2000-2045
Table 45: Influenza Disease Burden in U.S., by Age Group, 2019 and 2020 Influenza Season
Table 46: North America Market for Nanomaterials in Personalized Medicine, by Country, Through 2028
Table 47: Diabetes Estimates in Europe, by Country, 2000-2045
Table 48: European Market for Nanomaterials in Personalized Medicine, by Country, Through 2028
Table 49: Tuberculosis Burden of Asian Countries, by Country, 2019
Table 50: Diabetes Estimates for the Asia-Pacific Region, by Country, 2000-2045
Table 51: Asia-Pacific Market for Nanomaterials in Personalized Medicine, by Country, Through 2028
Table 52: Diabetes Estimates in the RoW, by Country, 2000-2045
Table 53: Estimation of New Cancer Cases in Africa, by Cancer Type, 2020 and 2024
Table 54: Rest of the World Market for Nanomaterials in Personalized Medicine, by Region, Through 2028
Table 55: Key Focus Areas in ESG Metrics
Table 56: ESG Rankings for Select Nanomaterials Personalized Medicine Companies, 2023
Table 57: Examples of Nanomaterials Used in Theranostics
Table 58: Global Patents on Nanotechnologies, by Country, 2017-2020
Table 59: Number of Patents, by Technology, 2001-2021*
Table 60: Protein Drugs
Table 61: Nanoparticle Systems Approved for Drug Delivery
Table 62: Major Strategic Alliances, 2018-2023
Table 63: Major Players in the Nanoparticles Drug Field
Table 64: Global Distribution of Nanobiotechnology and Nanomedicine Companies
Table 65: Bristol-Myers Squibb: Financial Performance, 2021 and 2022
Table 66: Bristol-Myers Squibb: Key Developments, 2019
Table 67: Camurus AB: Financial Performance, 2021 and 2022
Table 68: Camurus AB: Key Developments, 2019
Table 69: Cytimmune Sciences: News, 2021
Table 70: Eisai: Financial Performance, 2021 and 2022
Table 71: Eisai: News, 2021
Table 72: Gilead Sciences Inc.: Financial Performance, 2021 and 2022
Table 73: Ipsen Pharma: Financial performance, 2021 and 2022
Table 74: Acronyms Used in This Report
List of Figures
Figure A: Types of Nanomedicine Composed of Different Types of Materials
Summary Figure: Global Market Shares of Nanomaterials in Personalized Medicine, by Product Type, 2022
Figure 1: Types of Nanomedicines Composed of Different Types of Materials
Figure 2: Nanoparticles Used in Personalized Medicine
Figure 3: Nanotechnology Used in Personalized Medicine
Figure 4: Shares of New Cancer Cases, Women, 2020
Figure 5: Shares of New Cancer Cases, Men, 2020
Figure 6: Global Prevalence of Breast Cancer, by Country/Region, 2015-2025
Figure 7: Global Epidemiology of Colorectal Cancer, by Region, 2000-2030
Figure 8: Global Deaths, by Various Cancer Types, 2000-2030
Figure 9: Global Death Share, by Various Cancer Types, 2021
Figure 10: Cases of Diabetes Worldwide, by Type, 2019
Figure 11: Global Prevalence of Diabetes, by Type, 2018 and 2040
Figure 12: Protein Nanoparticle Fabrication and Performance Factors
Figure 13: Global Market for Proteins in Personalized Medicine, 2020-2028
Figure 14: Global Market for Monoclonal Antibodies in Personalized Medicine, 2020-2028
Figure 15: Global Market for Nanocrystals in Personalized Medicine, 2020-2028
Figure 16: Application of Liposomes in the Drug Delivery Arena
Figure 17: Global Market for Liposomes in Personalized Medicine, 2020-2028
Figure 18: Global Market for Gold Nanoparticles in Personalized Medicine, 2020-2028
Figure 19: Global Market for Quantum Dots in Personalized Medicine, 2020-2028
Figure 20: Global Market Shares of Nanomaterials in Personalized Medicine, by Region, 2022
Figure 21: North America Market for Nanomaterials in Personalized Medicine, by Country, 2020-2028
Figure 22: Cancer Diagnosis Share in Europe, by Gender, 2020
Figure 23: European Market for Nanomaterials in Personalized Medicine, by Country, 2020-2028
Figure 24: Asia-Pacific Market for Nanomaterials in Personalized Medicine, by Country, 2020-2028
Figure 25: Rest of the World Market for Nanomaterials in Personalized Medicine, by Region, 2020-2028
Figure 26: How a Strong ESG Proposition Benefits Businesses
Figure 27: ESG-Adoption Level Across All the Industries, 2021 and 2022
Figure 28: The Ten Business Sustainability Trends Identified for 2022
Figure 29: Key Sustainable Practices Being Implemented in Research Laboratories
Figure 30: Emerging Technologies in the Nanomaterials in Personalized Medicine Market
Figure 31: Global Market Shares of Nanoparticles in Personalized Medicine, by Company, 2022
Figure 32: Bristol-Myers Squibb: Financial Performance, 2021 and 2022
Figure 33: Bristol-Myers Squibb: Revenue Share, by Country/Region, 2022
Figure 34: Camurus AB: Financial Performance, 2021 and 2022
Figure 35: Camurus AB: Revenue Share, by Country/Region, 2022
Figure 36: Eisai: Financial Performance, 2021 and 2022
Figure 37: Eisai: Revenue Share, by Country/Region, 2022
Figure 38: Gilead Sciences Inc.: Financial Performance, 2021 and 2022
Figure 39: Gilead Sciences Inc.: Revenue Share, by Country/Region, 2022
Figure 40: Ipsen Pharma: Financial Performance, 2021 and 2022
Figure 41: Ipsen Pharma: Revenue Share, by Segment, 2022
Figure 42: Ipsen Pharma: Revenue Share, by Country/Region, 2022
